Revolutionary cancer diagnosis: Illuccix® available in Austria from now on!

Revolutionary cancer diagnosis: Illuccix® available in Austria from now on!

Österreich - On July 20, 2025, Telix Pharmaceuticals Limited received admission for Illuccix® (Gallium-68-Gozetotid injection) from the Federal Office of Health Care (BASG) in Austria. This new form of images is specially approved for the detection and localization of PSMA-positive lesions in adults with prostate cancer. Prostate cancer remains the most common cancer for men in Austria, with over 5,900 new cases annually, and is also the second most common cause of cancer in this population group, which in 2022 had over 1,300 deaths.

The indications for Illuccix are wide and include primary staging diagnostics in high-risk prostate cancer before a curative therapy, the investigation if you suspect recurrent prostate cancer with increasing PSA values after an already performed therapy and the identification of patients with PSMA-positive metastasized castration resistant Prostate cancer. Thanks to innovative PSMA-PET image units, the accuracy of the stages and the assessment of a biochemical recurrence is noticeably increased. This method increasingly replaces conventional processes such as bone scintigraphy and CT scans.

innovative imaging technology

The special PSMA PET-CT diagnostics, which is offered at the Cologne University Hospital, uses the feeling of feeling [68GA] PSMA. This molecule selectively binds to the prostate-specific membrane antigen (PSMA), which is present in high concentrations on the surfaces of prostate carcinoma cells. The method proved to be extremely sensitive to recurrence diagnosis, even in PSA values below 1 ng/ml, and can make local recurrence tumors and metastases visible.

Illuccix will be available from the sales partner THP Medical Products in Austria. Previously, the product has already been approved by several health authorities worldwide, including the FDA and the TGA. "PSMA diagnostics is an important scientific focus of our clinic," emphasizes the nuclear medicine of the Cologne University Hospital and emphasizes that a fluoride-marked variant of the PSMA venue ([18f] PSMA) is used internationally, which has potentially improved diagnostic properties.

growing interest in PSMA diagnostics

The growing interest in PSMA PET imaging is not only in Austria, but also internationally. Studies are increasingly demonstrating the advantages of these technologies. Since the introduction of this modern imaging process, a significant improvement in diagnosis and treatment of prostate cancer has been recorded. In view of the high incidence and the serious effects of the disease, education and awareness of innovative treatment approaches such as PSMA diagnostics also attract a broader public attention.

Overall, the admission of Illuccix in Austria marks significant progress in the fight against prostate cancer and offers patients a more precise and effective diagnostic possibility that may be life -saving.